Anbio Biotechnology

Anbio Biotechnology (ticker: NNNN) is an NASDAQ-listed in vitro & in vivo diagnostic substances company. DredgeCap's structured extraction of NNNN's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. NNNN reported $8.65M in revenue and $6.40M for the period ending 2025-12-31, with operating cash flow of -$6.74M. Cash and equivalents stood at $7.77M (down 34% year-over-year). Total assets of $30.24M exceed total liabilities of $88K. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.